Table 1. Main characteristics and results of the eligible studies.
|
NSCLC |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
All studies |
Any stage |
Locoregional (I–II) |
Surgical treatment (I–III) |
SCLC |
Neuroendocrine tumours |
|||||||
| Total | S | Total | S | Total | S | Total | S | Total | S | Total | S | |
| Number of studies | 28 (25) | 11 (11) | 7 (6) | 2 (2) | 6 (5) | 2 (2) | 8 (7) | 6 (6) | 4 (4) | 0 | 3 (3) | 1 (1) |
NSCLC=non-small cell lung cancer; SCLC=small cell lung cancer; S=number of studies identifying Bcl-2 positivity as a statistically significant good prognostic factor; ( )=number of studies evaluable for meta-analysis.